TY - JOUR
T1 - Outcome analysis of continuous intraoperative renal replacement therapy in the highest acuity liver transplant recipients
T2 - A single-center experience
AU - Zimmerman, Michael A.
AU - Selim, Motaz
AU - Kim, Joohyun
AU - Regner, Kevin
AU - Saeian, Kia
AU - Zanowski, Stephanie
AU - Martin, Alicia
AU - Connolly, Lois A.
AU - Lauer, Kathryn K.
AU - Woehlck, Harvey J.
AU - Hong, Johnny C.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/5
Y1 - 2017/5
N2 - Background Orthotopic liver transplantation is the definitive treatment modality for patients with end-stage liver disease. Pre–orthotopic liver transplantation renal dysfunction has a significant negative influence on outcomes post–orthotopic liver transplantation. Intraoperative renal replacement therapy is an adjunctive therapy to address the metabolic challenges during orthotopic liver transplantation in patients with a high acuity of illness. The impact of intraoperative renal replacement therapy on post–orthotopic liver transplantation outcomes, however, is unclear. Methods From October of 2012 to April of 2016, 96 adult patients underwent orthotopic liver transplantation for end-stage liver disease. Three groups were identified: (1) Group I: patients with pre–orthotopic liver transplantation renal dysfunction who underwent intraoperative renal replacement therapy, (2) Group II: patients with pre–orthotopic liver transplantation renal dysfunction who did not receive intraoperative renal replacement therapy, and (3) Group III: patients with orthotopic liver transplantation without evidence of pretransplant renal dysfunction. Results At 17.7 months follow-up, there was no difference in survival among the study groups. Physiologic model for end-stage liver disease at the time of orthotopic liver transplantation was significantly higher in both groups with renal dysfunction (I = 43, II = 39) than in Group III (18). Post–orthotopic liver transplantation, 12-month patient survival in Group II was 100%. While the model for end-stage liver disease score at orthotopic liver transplantation was significantly different between Group I and Group III, the 12-month, post–orthotopic liver transplantation patient survival was comparable at 78% vs 88%, respectively. Conclusion Intraoperative renal replacement therapy is a safe adjunctive therapy during liver transplantation of critically ill patients with renal dysfunction. Identifying patients who require intraoperative renal replacement therapy would improve intraoperative and post–liver transplant survival and may facilitate recovery of native kidney function after transplant.
AB - Background Orthotopic liver transplantation is the definitive treatment modality for patients with end-stage liver disease. Pre–orthotopic liver transplantation renal dysfunction has a significant negative influence on outcomes post–orthotopic liver transplantation. Intraoperative renal replacement therapy is an adjunctive therapy to address the metabolic challenges during orthotopic liver transplantation in patients with a high acuity of illness. The impact of intraoperative renal replacement therapy on post–orthotopic liver transplantation outcomes, however, is unclear. Methods From October of 2012 to April of 2016, 96 adult patients underwent orthotopic liver transplantation for end-stage liver disease. Three groups were identified: (1) Group I: patients with pre–orthotopic liver transplantation renal dysfunction who underwent intraoperative renal replacement therapy, (2) Group II: patients with pre–orthotopic liver transplantation renal dysfunction who did not receive intraoperative renal replacement therapy, and (3) Group III: patients with orthotopic liver transplantation without evidence of pretransplant renal dysfunction. Results At 17.7 months follow-up, there was no difference in survival among the study groups. Physiologic model for end-stage liver disease at the time of orthotopic liver transplantation was significantly higher in both groups with renal dysfunction (I = 43, II = 39) than in Group III (18). Post–orthotopic liver transplantation, 12-month patient survival in Group II was 100%. While the model for end-stage liver disease score at orthotopic liver transplantation was significantly different between Group I and Group III, the 12-month, post–orthotopic liver transplantation patient survival was comparable at 78% vs 88%, respectively. Conclusion Intraoperative renal replacement therapy is a safe adjunctive therapy during liver transplantation of critically ill patients with renal dysfunction. Identifying patients who require intraoperative renal replacement therapy would improve intraoperative and post–liver transplant survival and may facilitate recovery of native kidney function after transplant.
UR - http://www.scopus.com/inward/record.url?scp=85008237865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008237865&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2016.10.027
DO - 10.1016/j.surg.2016.10.027
M3 - Article
C2 - 28011008
AN - SCOPUS:85008237865
SN - 0039-6060
VL - 161
SP - 1279
EP - 1286
JO - Surgery (United States)
JF - Surgery (United States)
IS - 5
ER -